Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma

PURPOSE: Biomarkers are needed to stratify patients with stage II-III melanoma for clinical trials of adjuvant therapy because, while immunotherapy is protective, it also confers the risk of severe toxicity. We previously defined and validated a 53-immune gene melanoma immune profile (MIP) predictiv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Gartrell, Robyn D., Marks, Douglas K., Rizk, Emanuelle M., Bogardus, Margaret H., Gérard, Camille L., Barker, Luke W., Fu, Yichun, Esancy, Camden L., Li, Gen, Ji, Jiayi, Rui, Shumin, Ernstoff, Marc S., Taback, Bret, Pabla, Sarabjot, Chang, Rui, Lee, Sandra J., Krolewski, John J., Morrison, Carl, Saenger, Yvonne M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594682/
https://ncbi.nlm.nih.gov/pubmed/30647081
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-2847
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados